ArticleBMC psychiatry2025
The diagnostic potential of unconjugated bilirubin in schizophrenia and bipolar disorder.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSchizophrenia is not well differentiated from bipolar disorder when acute psychiatric symptoms are present. Recently, several studies have suggested a potential link between unconjugated bilirubin and schizophrenia and bipolar disorder, but the exact relationship has not been elucidated.
methodsTo compare the levels of unconjugated bilirubin in the blood of patients with schizophrenia and bipolar disorder and to analyze whether there is a potential causal relationship between unconjugated bilirubin and schizophrenia and bipolar disorder using mendelian randomization, and finally to validate the relationship between them by the clinical symptoms and the levels of unconjugated bilirubin before and after MECT.
resultsBlood levels of unconjugated bilirubin were significantly higher(P = 0.0001) in schizophrenia (11.53 ± 5.442 µmol/L) than in bipolar disorder (9.063 ± 3.463 µmol/L). Unconjugated bilirubin levels in the blood of patients with schizophrenia in the acute phase were significantly higher than those of patients with bipolar disorder, and mendelian randomization analysis showed a significant causal relationship between unconjugated bilirubin and schizophrenia (OR = 1. 131, 95% CI: 1.034-1.237, P = 0.007). Patients with schizophrenia treated with MECT showed a significant reduction in clinical symptoms and a significant decrease in unconjugated bilirubin.
conclusionsThis study found that patients with schizophrenia had significantly higher unconjugated bilirubin levels compared to patients with bipolar disorder. Mendelian randomization results suggest a positive causal relationship between unconjugated bilirubin and schizophrenia. Decreases in unconjugated bilirubin after MECT alleviated clinical symptoms of schizophrenia. It provides a new idea for clinical diagnosis of schizophrenia and bipolar disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.